Market-Moving News for May 21st
$BDRX
$MMAT
$SPT
Biotechnology: Pharmaceutical Preparations
Health Care
Semiconductors
Technology
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 6/3/2025 | $24.00 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/19/2024 | $28.00 | Sector Perform | Scotiabank | |
| 8/22/2024 | $28.00 | Sector Weight → Underweight | KeyBanc Capital Markets | |
| 5/3/2024 | Outperform → Mkt Perform | William Blair | ||
| 5/3/2024 | $80.00 → $44.00 | Buy → Neutral | Goldman | |
| 5/3/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | ||
| 5/3/2024 | $72.00 → $45.00 | Outperform → Neutral | Robert W. Baird | |
| 5/3/2024 | $66.00 → $40.00 | Overweight → Neutral | Piper Sandler |
4 - Sprout Social, Inc. (0001517375) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
Cantor Fitzgerald downgraded Sprout Social from Overweight to Neutral and set a new price target of $24.00
Scotiabank initiated coverage of Sprout Social with a rating of Sector Perform and set a new price target of $28.00
KeyBanc Capital Markets downgraded Sprout Social from Sector Weight to Underweight and set a new price target of $28.00
8-K - Sprout Social, Inc. (0001517375) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST). The compound also has the potential to be useful
CHICAGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the fourth quarter ending December 31, 2025 after market close on Thursday, February 26, 2026. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, February 26, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/240954313?pwd=Fg5h0XTc. The live webcast of the conference cal
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl
4 - Sprout Social, Inc. (0001517375) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl
September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3
CHICAGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the fourth quarter ending December 31, 2025 after market close on Thursday, February 26, 2026. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, February 26, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/240954313?pwd=Fg5h0XTc. The live webcast of the conference cal
CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its third quarter ended September 30, 2025. "Our team delivered strong results in the third quarter, highlighted by 17% cRPO growth and strong profitability," said Ryan Barretto, CEO of Sprout Social. "We saw strong execution in our enterprise segment as we remain committed to strengthening our enterprise presence through customer adoption, account expansion, and strategic partnerships." Third Quarter 2025 Financial Highlights Revenue Revenue was $115.6 mi
CHICAGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the third quarter ending September 30, 2025 after market close on Wednesday, November 5, 2025. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Wednesday, November 5, 2025. Online registration for this event conference call can be found at https://events.q4inc.com/attendee/296246685. The live webcast of the conference call can be acc
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Sprout Social, Inc. (0001517375) (Subject)